

NZX Limited
WELLINGTON

TruScreen Receives CFDA Approval for its Second Generation Device in China

Cervical cancer screening technology company, TruScreen Limited (NZAX: TRU) is pleased to advise that the China Food and Drug Administration (CFDA) have issued its formal certificate of approval permitting the commercial supply and sale in China of the new upgraded TruScreen2 cervical cancer screening device.

TruScreen CEO Mr Martin Dillon said “CFDA registration is, by global standards, an extremely rigorous validation process which certifies the engineering, quality and efficacy of our product for use in our major market , China. The company has been steadily building up its inventories in anticipation of receiving the registration and will now commence export sales of the new device to China as soon as practicably possible.”

ENDS

For more information visit www.truscreen.com or contact:

Martin Dillon

TruScreen Chief Executive Officer

Email: martindillon@truscreen.com

Media Liaison

Jackie Ellis

Email: jackie@ellisandco.co.nz

Phone: +64 27 246 2505

About TruScreen:

TruScreen’s real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection.

